Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects
Launched by JW PHARMACEUTICAL · Jul 28, 2011
Trial Information
Current as of August 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy male volunteers
- • Age 20-55 years at the time of Screening
- • BMI 19-26 kg/m2 at the time of Screening
- Exclusion Criteria:
- • Received other investigational drug within 90 days prior to the first dose of study drug
About Jw Pharmaceutical
JW Pharmaceutical is a leading South Korean biopharmaceutical company dedicated to advancing healthcare through innovative research and development of novel therapeutics. With a strong focus on oncology, neurology, and rare diseases, JW Pharmaceutical leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company is committed to conducting high-quality clinical trials that adhere to rigorous ethical standards, ensuring patient safety and efficacy of its products. Through strategic partnerships and collaborations, JW Pharmaceutical aims to deliver impactful therapies that enhance the quality of life for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Kyun Seop Bae, MD
Principal Investigator
Asan Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials